SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nxera Pharma Signs QUVIVIQ Agreement With Synmosa Across Eight Asia-Pacific Markets

Nxera Pharma Japan entered an exclusive license, supply and commercialization agreement with Synmosa for QUVIVIQ (daridorexant) across eight Asia-Pacific markets.

4565

Story updates

07:57:02 AM UTC
SquawkNews
Nxera Pharma signed an exclusive license, supply and commercialization agreement with Synmosa for QUVIVIQ (daridorexant) in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand, with upfront, regulatory milestones, royalties and supply revenue.Material Detai…

Related stories